Repligen shells out $150M for New Hampshire biotech
September 16, 2021 at 13:17 PM EDT
Waltham drug developer Repligen is paying $150 million in cash and stock to acquire a New Hampshire-based chromatography developer called Avitide Inc.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|